Related references
Note: Only part of the references are listed.Silodosin for Benign Prostatic Hyperplasia
Matthew A. Cantrell et al.
ANNALS OF PHARMACOTHERAPY (2010)
Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations
Gabriela Franco-Salinas et al.
CLINICAL PHARMACOKINETICS (2010)
3D-QSAR studies on unsaturated 4-azasteroids as human 5α-reductase inhibitors: A self organizing molecular field analysis approach
Saurabh Aggarwal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study
Claus G. Roehrborn et al.
EUROPEAN UROLOGY (2010)
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study
F. Montorsi et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Effect of Dutasteride on the Risk of Prostate Cancer.
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
An overview on 5α-reductase inhibitors
Saurabh Aggarwal et al.
STEROIDS (2010)
Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?
Stavros Gravas et al.
CURRENT OPINION IN UROLOGY (2009)
The Influence of Baseline Parameters on Changes in International Prostate Symptom Score with Dutasteride, Tamsulosin, and Combination Therapy among Men with Symptomatic Benign Prostatic Hyperplasia and an Enlarged Prostate: 2-Year Data from the CombAT Study
Claus G. Roehrborn et al.
EUROPEAN UROLOGY (2009)
Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men
P. Abrams et al.
JOURNAL OF UROLOGY (2009)
Role of Invasive Urodynamic Testing in Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms
Jennifer L. Mehdizadeh et al.
UROLOGIC CLINICS OF NORTH AMERICA (2009)
Clinical management of lower urinary tract symptoms with combined medical therapy
Claus G. Roehrborn
BJU INTERNATIONAL (2008)
Dutasteride - A review of its use in the management of prostate disorders
Susan J. Keam et al.
DRUGS (2008)
A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia
J. C. Nickel et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
Claus G. Roehrborn et al.
JOURNAL OF UROLOGY (2008)
Do alpha(1)-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
Maurits M. Barendrecht et al.
NEUROUROLOGY AND URODYNAMICS (2008)
Prediction of α1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia
Shizuo Yamada et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2007)
Intraloperative floppy-iris syndrome associated with α1-adrenoreceptors -: Comparison of tamsulosin and alfuzosin
Marie-Claude Blouin et al.
JOURNAL OF CATARACT AND REFRACTIVE SURGERY (2007)
The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia
R. Wurzel et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2007)
Safety and tolerability of treatment for BPH
Francesco Montorsi et al.
EUROPEAN UROLOGY SUPPLEMENTS (2006)
Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement
Marc Gittelman et al.
JOURNAL OF UROLOGY (2006)
Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5α-reductase inhibitor dutasteride
GL Andriole et al.
JOURNAL OF UROLOGY (2006)
A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder
CR Chapple et al.
EUROPEAN UROLOGY (2006)
Effects of alpha 1-adrenoceptor antagonists on male sexual function
MM van Dijk et al.
DRUGS (2006)
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia
J Nordling
BJU INTERNATIONAL (2005)
The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®)
MC Michel et al.
EUROPEAN UROLOGY SUPPLEMENTS (2005)
Comparison of vascular α1-adrenoceptor antagonism of tamsulosin in oral controlled absorption system (OCAS) and modified release (MR) formulations
MC Michel et al.
EUROPEAN UROLOGY SUPPLEMENTS (2005)
Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation
MC Michel et al.
EUROPEAN UROLOGY SUPPLEMENTS (2005)
Dutasteride:: a novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia
B Djavan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2005)
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor
RV Clark et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia
CG Roehrborn et al.
UROLOGY (2004)
α1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia
CG Roehrborn et al.
JOURNAL OF UROLOGY (2004)
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia
CG Roehrborn et al.
JOURNAL OF UROLOGY (2004)
Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial
G Andriole et al.
JOURNAL OF UROLOGY (2004)
Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia
F Debruyne et al.
EUROPEAN UROLOGY (2004)
State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
B Djavan et al.
UROLOGY (2004)
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
JD McConnell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride
J Barkin et al.
EUROPEAN UROLOGY (2003)
Comparative pharmacophore development for inhibitors of human and rat 5-α-reductase
J Faragalla et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2003)
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies
CG Roehrborn et al.
BJU INTERNATIONAL (2003)
The influence of finasteride on the development of prostate cancer
IM Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia
RS Kirby
BJU INTERNATIONAL (2003)
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial
RS Kirby et al.
UROLOGY (2003)
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
CG Roehrborn et al.
UROLOGY (2002)
Medical therapy for benign prostatic hyperplasia: A review of the literature
GM Clifford et al.
EUROPEAN UROLOGY (2000)
Share Paper
